【摘要】 急性髓系白血病(acute myeloid leukemia,AML)是一种临床和遗传异质性疾病且预后不良。基因组学和分子生物学的最新进展使得对该疾病有了进一步的了解。作为单一药物,去甲基化剂(hypomethy latingagents,HMAs)仅可诱导15%～25%的完全缓解率,但目前的数据表明,在使用HMAs后观察到的中位总生存期(overallsur vival,OS)与强化治疗后观察到的中位OS相当。一些接受HMAs治疗的患者是否可获得长期生存尚不清楚。HMAs与新药的结合现已得到广泛研究,且取得了相当好的疗效。更多还原

【Abstract】 Acute myeloid leukemia(AML) is a clinical and genetic heterogeneous disease with poor prognosis. Recent advances in genomics and molecular biology have led to a better understanding of the disease. The hypomethylating agents(HMAs) only induced a complete response rate of 15% to 25%. Current data show that the median overall survival observed after HMAs is comparable to that observed after intensive therapy. It is not clear whether patients who receiving HMAs therapy can achieve long-term survival. The combination of HMAs and new drugs has been extensively studied, and a large number of reports have been reported on the combination of HMAs and different drugs for AML, and achieved fairly good results.更多还原